0001347166-11-000004.txt : 20110518 0001347166-11-000004.hdr.sgml : 20110518 20110518184013 ACCESSION NUMBER: 0001347166-11-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110516 FILED AS OF DATE: 20110518 DATE AS OF CHANGE: 20110518 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yonehiro Grant CENTRAL INDEX KEY: 0001428666 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28401 FILM NUMBER: 11856012 MAIL ADDRESS: STREET 1: C/O MAXYGEN, INC. STREET 2: 515 GALVESTON DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MAXYGEN INC CENTRAL INDEX KEY: 0001068796 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 770449487 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 515 GALVESTON DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 6502985300 MAIL ADDRESS: STREET 1: 515 GALVESTON DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 edgar.xml PRIMARY DOCUMENT X0303 4 2011-05-16 1 0001068796 MAXYGEN INC MAXY 0001428666 Yonehiro Grant C/O MAXYGEN, INC. 515 GALVESTON DRIVE REDWOOD CITY 94063 0 1 0 0 Senior Vice President Common Stock 2011-05-16 4 M 0 19800 A 101876 D Common Stock 2011-05-16 4 D 0 19800 D 82076 D Common Stock 4175 I Held by Maxygen, Inc. 401(k) plan Performance Units 2011-05-16 4 M 0 19800 0 D Common Stock 19800 0 D In connection with the acquisition by Astellas Bio Inc. of all of the issuer's equity interest in Perseid Therapeutics LLC, a portion of the contingent performance units held by the reporting person vested and were settled by the issuer entirely in cash. Each vested contingent performance unit represented the right to receive one share of issuer common stock plus all qualifying dividend payments and other distributions to stockholders on a per share basis (or the value thereof). All remaining unvested contingent performance units held by the reporting person expired immediately upon settlement. The value of each vested contingent performance unit is equal to the per share price of common stock of the issuer as of the May 16, 2011 closing date of the acquisition by Astellas Bio Inc. of all of the issuer's equity interest in Perseid Therapeutics LLC ($5.10), plus the value of the per share amount of the special cash distribution and the distribution of shares of Codexis, Inc. common stock by the issuer in December 2010. /s/ John Borkholder - Attorney-in-fact 2011-05-18